Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2022-04-21 | Dr. Hallam received a B.S. in biology from the University of Illinois at Urbana-Champaign, a Ph.D. in neuroscience from the University of California, Davis, and an MBA from the University of Southern California. |
| 2022-08-31 | Thomas Hallam, Ph.D. - Chief Executive Officer |
| 2022-08-31 | Thomas Hallam, Ph.D. Chief Executive Officer ... In accordance with the merger transaction with Seneca Biopharma, Inc. ("Seneca") effected April 27, 2021, the board of directors of Seneca (the "Seneca Board") appointed Thomas Hallam, Ph.D., James R. Neal, Stephanie Diaz, Robert J. Trenschel, D.O. and Don Williams to the Board. |
| 2024-02-06 | Thomas Hallam, Ph.D.(5) Includes (i) 31 shares of common stock and (ii) 800 shares of common stock underlying common stock purchase warrants. Dr. Hallam ceased to be an officer and director of the Company effective October 11, 2022. |
Data sourced from SEC filings. Last updated: 2026-03-09